MetaCap

Obsidian Therapeutics (OBX) vs Oric Pharmaceuticals (ORIC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Oric Pharmaceuticals is the larger company by market cap ($764.9 million vs $741.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OBX-31.43%ORIC-38.77%
+107%+27%-52%
Jul 27, 20261 yearNov 20, 2026
OBX-23.18%ORIC-33.51%
+82%+21%-39%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OBX versus ORIC key metrics
MetricOBXORIC
Share price$12.00$7.36
Market cap$741.29M$764.94M
1-day change-1.23%-4.42%
YTD return—-10.02%
1-year return—-36.66%
5-year return—-48.64%
EPS (TTM)$-6.52$-1.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-129.47M
52-week high$49.97$14.68
52-week low$9.60$7.23
Distance from 52-week high-75.99%-49.86%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+222.25%+194.97%
Average volume511.50K1.59M
Shares outstanding61.77M103.93M
Employees87111
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Obsidian Therapeutics

OBX stock →

Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies.

Health Care · Biotechnology: Pharmaceutical Preparations · 87 employees

About Oric Pharmaceuticals

ORIC stock →

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.

Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees

OBX vs ORIC FAQ

Which is bigger, Obsidian Therapeutics or Oric Pharmaceuticals?

Oric Pharmaceuticals (ORIC) is larger, with a market capitalization of $764.94M compared with $741.29M for Obsidian Therapeutics (OBX).

Are Obsidian Therapeutics and Oric Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons